Novartis CEO Calls Potential Schering-Plough Merger “Very Interesting”
This article was originally published in The Tan Sheet
Executive Summary
A Novartis/Schering-Plough merger would increase Novartis' OTC portfolio by about 57% to $2.77 bil. and give the Swiss firm control over the formidable Claritin allergy and hives relief franchise
You may also be interested in...
Sanofi-Aventis Combo Leaves Allegra In Rx Territory For Now
Allegra's status as a prescription-only drug appears to be secure in the near-term now that Aventis has accepted Sanofi-Synthelabo's sweetened hostile bid for the company
Sanofi-Aventis Combo Leaves Allegra In Rx Territory For Now
Allegra's status as a prescription-only drug appears to be secure in the near-term now that Aventis has accepted Sanofi-Synthelabo's sweetened hostile bid for the company
Sanofi-Aventis Combo Leaves Allegra In Rx Territory For Now
Allegra's status as a prescription-only drug appears to be secure in the near-term now that Aventis has accepted Sanofi-Synthelabo's sweetened hostile bid for the company